KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
110 hedge funds and large institutions have $567M invested in KalVista Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 25 closing their positions.
2.56% more ownership
Funds ownership: 97.03% → 99.59% (+2.6%)
3% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 38
6% less funds holding
Funds holding: 117 → 110 (-7)
6% less capital invested
Capital invested by funds: $605M → $567M (-$37.5M)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
51% less call options, than puts
Call options by funds: $2.45M | Put options by funds: $5.04M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$41.3M |
| 2 |
DM
Deerfield Management
New York
|
+$29.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.47M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$6.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$18.5M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$14.2M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.78M |
KALV Hedge Fund Activity: Q2 2021 in Review
110 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2021, worth a combined $567M — down 6.2% from $605M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of KALV and 18 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 39 added.
The largest buyer was RA Capital Management, adding an estimated $41.3M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $19.3M sold.
- 110 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2021, down from 117 in Q1 2021.
- Funds reported $567M of KalVista Pharmaceuticals stock for Q2 2021, down 6.2% quarter-over-quarter.
- 18 funds opened new KalVista Pharmaceuticals positions in Q2 2021 and 25 closed out, a net change of -7 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2021 was RA Capital Management, an estimated $41.3M added.
- The largest KalVista Pharmaceuticals seller in Q2 2021 was Cormorant Asset Management, an estimated $19.3M sold.
Based on aggregated 13F filings for Q2 2021.